Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

为解决胰腺癌治疗难题，浙江大学医学院附属第一医院的研究人员开展 MMP-28 与胰腺癌关系的研究，发现 MMP-28 影响 EGFR 抑制剂疗效，可作生物标志物。推荐科研读者阅读，助力探索胰腺癌新疗法。 在癌症的众多特征中，持续的增殖信号传导就像是肿瘤生长的 ...

Black Diamond Therapeutics presents a compelling investment opportunity with strong potential, balanced by inherent biotech ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target.

Checkpoint Therapeutics gains approval for cosibelimab but faces financial challenges and tough competition. Learn more about CKPT stock here.

For example, EGFR 19 deletions and EGFR L858R point mutations respond well to tyrosine kinase inhibitors (TKIs), which are also called EGFR inhibitors. Drugs that target the EGFR protein and block ...

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization's updated clinical practice guideline. In a synopsis of the recently ...

Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTCL The combination of ...